Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | TK1 | P04183 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011590 | 0.88 | BCHE (0.56) | BCHETK1LMNATSHRALB | |
| SCHEMBL16127042 | 0.88 | BCHE (0.56) | BCHETK1LMNATSHRALB | |
| SCHEMBL26195062 | 0.87 | BCHE (0.55) | BCHETK1LMNATSHRALB | |
| SCHEMBL1878103 | 0.87 | BCHE (0.55) | BCHETK1LMNATSHRALB | |
| SCHEMBL3611845 | 0.87 | BCHE (0.55) | BCHETK1LMNATSHRALB | |
| SCHEMBL25708175 | 0.87 | BCHE (0.55) | BCHETK1LMNATSHRALB | |
| SCHEMBL14534947 | 0.86 | BCHE (0.52) | BCHETK1LMNAALBPKM | |
| SCHEMBL18250944 | 0.86 | BCHE (0.52) | BCHETK1LMNAALBPKM | |
| SCHEMBL24500263 | 0.85 | BCHE (0.53) | BCHETK1LMNATSHRALB | |
| SCHEMBL18020480 | 0.85 | BCHE (0.53) | BCHETK1LMNATSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054720-A1 | Antisense Oligonucleotides Targeting ATXN3 | HOFFMANN-LA ROCHE INC. | 2023-02-23 | — | — | US | disclosed |
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| US-10865414-B2 | Modulators of DNM2 expression | IONIS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190241896-A1 | MODULATORS OF DNM2 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054720-A1 | Antisense Oligonucleotides Targeting ATXN3 | ATXN2, ATXN2L, ATXN10 | BCHE 3655/4885TK1 891/4885LMNA 280/4885 |
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | MAPT, GAP43, RNMT | BCHE 1934/4885TK1 192/4885LMNA 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.